With the historic Food and Drug Administration (FDA) approval of treatments that slow the progression of Alzheimer’s in the early stages, access to diagnostics and treatment are even more critical to ensure individuals receive the most benefit at the earliest point possible. State policymakers can take action by:

• Ensuring state-regulated insurance plans provide appropriate coverage to FDA-approved treatments and diagnostics for individuals living with Alzheimer’s and other dementias.